Pfizer Inc. has obtained a European patent (EP4562017A1) for novel Acetyl-CoA Carboxylase (ACC) inhibitor compounds. The patent application claims priority and covers pharmaceutical compositions containing these inhibitors for therapeutic use. The compounds are classified under IPC class C07D 513/10, with potential applications indicated for dermatological conditions (A61P 17/10) and inflammatory diseases (A61P 29/00). The patent designates 27 European Contracting States for protection.

Pharmaceutical companies developing ACC inhibitors or related metabolic disorder therapeutics should review this patent for freedom-to-operate considerations. Competitors active in ACC inhibitor research should assess potential overlap with their own compound portfolios. The patent establishes Pfizer's intellectual property rights in this therapeutic space across the designated European jurisdictions.